While COVID-19 has infected millions of people worldwide and killed hundreds of thousands, there is currently no vaccine. In response, researchers have been evaluating the effectiveness of various antiviral drugs as possible COVID-19 treatments.
A new set of recommendations for health care workers on the front lines, to help them make decisions on how to treat the most critical COVID-19 patients, those with severe lung or heart failure, has been published.
Most newly discharged patients who recently recovered from COVID-19 produce virus-specific antibodies and T cells, suggests a study published on May 3rd in the journal Immunity, but the responses of different patients are not all the same. While the 14 patients examined in the study showed wide-ranging immune responses, results from the 6 of them that were assessed at two weeks after discharge suggest that antibodies were maintained for at least that long. Additional results from the study indicate which parts of the virus are most effective at triggering these immune responses and should therefore be targeted by potential vaccines.
It is not clear why immune responses varied widely across the patients. The authors say this variability may be related to the initial quantities of virus that the patients encountered, their physical states, or their microbiota. Other open questions include whether these immune responses protect against COVID-19 upon re-exposure to SARS-CoV-2, as well as which types of T cells are activated by infection with the virus. It is also important to note that the laboratory tests that are used to detect antibodies to SARS-CoV-2 in humans still need further validation to determine their accuracy and reliability.
“These findings suggest both B and T cells participate in immune-mediated protection against the viral infection,” says co-senior study author Chen Dong of Tsinghua University. “Our work has provided a basis for further analysis of protective immunity and for understanding the mechanism underlying the development of COVID-19, especially in severe cases. It also has implications for designing an effective vaccine to protect against infection.”
The breakthrough, which identified the location and function of every human gene, offered the promise of medical care tailored specifically to individual patients, based on their personal genetic makeup.
When researchers identified a gene associated with a 44 per cent risk of breast cancer in women, for example, it seemed that protecting them might be as simple as deactivating that gene.
But the promise of such personalized medicine has not fully materialized, say two McMaster researchers, because the full sophistication of the genetic blueprint has a more complex and far-reaching influence on human health than scientists had first realized.
Augmented reality has been the next big thing for a while, but we haven’t seen many practical applications. Here’s a tool that looks useful, though: using AR and AI to copy and paste objects from the real world to your computer using just your phone.
But one of the biggest technical questions still remains: How much data should be transferred from the ATS to the cockpit of the manned aircraft controlling it, and when does that turn into information overload? That question is one Boeing wants to answer more definitively once ATS makes its first flight later this year and moves into its experimentation phase, Arnott said.
“There’s a lot for us to figure out [on] what’s that right level of information feed and direction. One of the great benefits of working with the Royal Australian Air Force is having the real operators [give feedback],” he said. “We don’t have all the answers yet. We have a lot of understanding through our surrogate simulator and surrogate testing that we’re doing, but we will prove that out.”
Boeing first introduced the Airpower Teaming System at the Australian International Airshow at Avalon in February 2019, when the company unveiled a full-scale model. Since then, the company has moved quickly to fabricate the first of three aircraft, completing the fuselage structure this February. In April, the aircraft stood on its own wheels for the first time and powered on.
The companies hope their team up will nab one of two spots in the competition, to be awarded later this year.
Despite the traditional view that species do not exchange genes by hybridisation, recent studies show that gene flow between closely related species is more common than previously thought. A team of scientists from Uppsala University and Princeton University now reports how gene flow between two species of Darwin’s finches has affected their beak morphology. The study is published today in Nature Ecology and Evolution.
Darwin’s finches on the Galápagos Islands are an example of a rapid adaptive radiation in which 18 species have evolved from a common ancestral species within a period of 1–2 million years. Some of these species have only been separated for a few hundred thousand years or less.
Rosemary and Peter Grant of Princeton University, co-authors of the new study, studied populations of Darwin’s finches on the small island of Daphne Major for 40 consecutive years and observed occasional hybridisation between two distinct species, the common cactus finch and the medium ground finch. The cactus finch is slightly larger than the medium ground finch, has a more pointed beak and is specialised to feed on cactus. The medium ground finch has a blunter beak and is specialised to feed on seeds.
In the absence of a specific vaccine, there has been much interest in alternative treatments and strategies to help minimise the effects of infection with COVID-19.
One strategy attracting much interest in the media is the importance of achieving sufficient vitamin D levels, and the topic has also been the subject of recent academic articles.1,2 While both articles discuss the potential role of vitamin D in the immune system, they also highlight the lack of direct clinical studies in those with COVID-19. However, a recent research letter3 provides some tentative evidence of the impact of vitamin D status on the severity of COVID-19 symptoms.
The test came out of DARPA, the U.S. military’s research division, and may be granted an accelerated emergency use authorization by the FDA by the end of the week, according to The Guardian.
If the test works as expected, it could play a major role in preventing future outbreaks by letting people know they need to self-isolate well before they start spreading the coronavirus.
“The concept fills a diagnostic gap worldwide,” Dr. Brad Ringeisen, head of DARPA’s biological technologies office, told The Guardian. He added that, should the FDA approve the test for use, it could be “absolutely a gamechanger.”
